BioAge Labs, Inc. SEC filings BIOA
BioAge Labs, Inc. has 157 filings in SEC EDGAR's recent list, going back to Feb 13, 2024. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 144 | Notice of proposed sale | Jun 30, 2026 | — |
| 144 | Notice of proposed sale | Jun 29, 2026 | — |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 27, 2026 | — |
| 4 | Insider transaction | Apr 24, 2026 | Apr 23, 2026 |
| 4 | Insider transaction | Apr 3, 2026 | Apr 1, 2026 |
| 144 | Notice of proposed sale | Apr 1, 2026 | — |
| 4 | Insider transaction | Mar 3, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 3, 2026 | Mar 1, 2026 |
| 144 | Notice of proposed sale | Mar 2, 2026 | — |
| 4 | Insider transaction | Feb 19, 2026 | Feb 17, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 17, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 17, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 17, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 17, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| 4 | Insider transaction | Feb 3, 2026 | Feb 2, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Feb 1, 2026 |
| 144 | Notice of proposed sale | Feb 2, 2026 | — |
| 4 | Insider transaction | Jan 21, 2026 | Jan 16, 2026 |
| 4 | Insider transaction | Jan 15, 2026 | Jan 13, 2026 |
| 4 | Insider transaction | Jan 15, 2026 | Jan 13, 2026 |
| 144 | Notice of proposed sale | Jan 13, 2026 | — |
| 144 | Notice of proposed sale | Jan 13, 2026 | — |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 144 | Notice of proposed sale | Jan 2, 2026 | — |
| 4 | Insider transaction | Dec 11, 2025 | Dec 9, 2025 |
| 144 | Notice of proposed sale | Dec 9, 2025 | — |
| 4 | Insider transaction | Dec 5, 2025 | Dec 4, 2025 |
| 144 | Notice of proposed sale | Dec 4, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| 4 | Insider transaction | Aug 11, 2025 | Aug 7, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 5, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 5, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 5, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 5, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 5, 2025 |
| 4/A | Filing | Mar 10, 2025 | Apr 17, 2024 |
| 4 | Insider transaction | Mar 10, 2025 | Sep 27, 2024 |
| 4/A | Filing | Feb 25, 2025 | Feb 18, 2025 |
| 4 | Insider transaction | Feb 20, 2025 | Feb 18, 2025 |
| 4 | Insider transaction | Feb 20, 2025 | Feb 18, 2025 |
| 4 | Insider transaction | Feb 20, 2025 | Feb 18, 2025 |
| 4 | Insider transaction | Feb 20, 2025 | Feb 18, 2025 |
| 4 | Insider transaction | Feb 20, 2025 | Feb 18, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| 4 | Insider transaction | Dec 20, 2024 | Dec 18, 2024 |
| SC 13G | Ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 12, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Oct 7, 2024 | — |
| SC 13D | Ownership over 5% (active) | Oct 4, 2024 | — |
| 4 | Insider transaction | Oct 3, 2024 | Oct 1, 2024 |
| 4 | Insider transaction | Oct 1, 2024 | Sep 27, 2024 |
| SC 13D | Ownership over 5% (active) | Sep 30, 2024 | — |
| 4 | Insider transaction | Sep 27, 2024 | Sep 27, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Sep 25, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Apr 17, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Sep 25, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Apr 17, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Mar 26, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Aug 19, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Apr 17, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
Showing 87 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIOA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1709941
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.